A New Type of Prodrug of Catecholamines: An Opportunity to Improve the Treatment of Parkinson's Disease-Reference-Cited by-同舟云学术

A New Type of Prodrug of Catecholamines: An Opportunity to Improve the Treatment of Parkinson's Disease

Published:2002-05-10 Issue:12 Volume:45 Page:2349-2351
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Venhuis Bastiaan J.¹,Wikström Håkan V.¹,Rodenhuis Nienke¹,Sundell Staffan¹,Dijkstra Durk¹

Affiliation:

1. Department of Medicinal Chemistry, University Centre for Pharmacy, University of Groningen, Antonius Deusinglaan 1, NL-9713 AV Groningen, The Netherlands, and Department of Medical Biochemistry, University of Göteborg, Box 440, SE-405 30 Göteborg, Sweden

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm025508m

Reference20 articles.

1. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists

2. History of levodopa and dopamine agonists in Parkinson's disease treatment

3. Adjuncts to levodopa therapy: Dopamine agonists

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification;European Journal of Medicinal Chemistry;2022-07

2. Current approaches to the treatment of Parkinson’s Disease;Bioorganic & Medicinal Chemistry Letters;2017-09

3. HQSAR and molecular docking studies of furanyl derivatives as adenosine A2A receptor antagonists;Medicinal Chemistry Research;2016-04-15

4. Prodrug Approaches to Drug Delivery;Drug Delivery;2016-03-25

5. Designing Prodrugs and Bioprecursors;The Practice of Medicinal Chemistry;2015